Interesting COV Put And Call Options For February 22nd

Investors in Covidien plc ( COV) saw new options begin trading this week, for the February 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the COV options chain for the new February 22nd contracts and identified one put and one call contract of particular interest.

The put contract at the $67.50 strike price has a current bid of $1.00. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $67.50, but will also collect the premium, putting the cost basis of the shares at $66.50 (before broker commissions). To an investor already interested in purchasing shares of COV, that could represent an attractive alternative to paying $68.85/share today.

Because the $67.50 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 63%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.48% return on the cash commitment, or 15.02% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of Stocks Analysts Like »

Below is a chart showing the trailing twelve month trading history for Covidien plc, and highlighting in green where the $67.50 strike is located relative to that history:

If you liked this article you might like

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Mallinckrodt Buys Ikaria in $2.3 Billion Hospital Treatment Deal

Stryker and Smith & Nephew Are the Stars to Watch in Medtech's 2015 Merger Dance

Medtronic Avoids U.S. Taxes While Saddling Shareholders With a Hefty Tax Bill

Trim Positions in Stryker Ahead of Fourth-Quarter Earnings; Buy on Pullback